Roivant Sciences

Roivant Sciences is a healthcare company focused on applying technology to drug development. Roivant builds subsidiary biotech and healthcare technology companies. Roivant was founded by Vivek Ramaswamy in 2014.
History.
Vivek Ramaswamy founded Roivant Sciences in 2014. Focused on aligning incentives and improving capital efficiency, Ramaswamy's initial strategy was to in-license drug candidates and create subsidiaries focused on distinct therapeutic areas. This strategy expanded to include developing earlier stage drug candidates and platform technologies. Roivant is a parent company to over a dozen subsidiaries ranging from Immunovant Sciences, a majority-owned public company focused on autoimmune diseases, to privately held Dermavant Sciences, focused on medical dermatology.
Roivant also develops healthcare technologies through investments in Datavant, which helps healthcare institutions safely share data, and Lokavant, which integrates clinical trial data sources to identify and mitigate risks in pharmaceutical development. As of 2019, Roivant had over 40 investigational drugs in development in 14 therapeutic areas across its family companies. 
In addition to Vivek Ramaswamy, the company's leadership includes: Mayukh Sukhatme, Matthew Gline, Eric Venker, Rakhi Kumar, and Ben Zimmer. As of 2017, Roivant was valued at $7 billion.
At the end of 2019, Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma and transferred its ownership stake in five of its subsidiaries: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences, which now sit under Sumitovant Biopharma. The deal included the option for Sumitomo to acquire up to 6 additional subsidiaries.
In April 2020, Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome (ARDS). Additionally, in April, Datavant Sciences announced that its technology is being used to create a pro-bono COVID-19 research database to help public health and policy researchers combat the pandemic.
In January 2021, Vivek Ramaswamy stepped down as CEO and became executive chairman. Matt Gline, previously the company's chief financial officer, became CEO.
In February 2021, Roivant Sciences acquired Silicon Therapeutics, a small-molecule drug designer and computational physics platform, for $450 million in Roivant equity. 
Subsidiaries & Former Subsidiaries.
As of April 2020, the company's subsidiaries include:
The following subsidiaries were previously a part of Roivant, but were included as part of a strategic transaction with Sumitomo Dainippon Pharma which closed in December 2019:
Roivant is a major shareholder of Datavant, which it co-founded alongside Travis May to break down silos between healthcare datasets and connect the world's health data. In October 2020, Datavant announced fundraising from Roivant Sciences alongside Transformation Capital, Johnson & Johnson, and Cigna. 
In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries. In December 2019, Roivant transferred five of its subsidiaries for dollars — Myovant, Urovant, Enzyvant, Altavant and Spirovant, in addition to a greater than 10% share in itself — to Sumitomo Dainippon Pharma.
In March 2020, Roivant announced it is developing gimsilumab, an anti-GM-CSF monoclonal antibody, to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19.
In April 2020, Roivant started giving US COVID-19 patients their experimental medicine, Gimsilumab.